BIO Ignores Calls to Disavow Catalyst Pharmaceuticals.
Medicare spent nearly $2 billion on H.P. Acthar Gel from 2011-2016, according to the agency's data — even though some doctors say an equally effective treatment would have cost a tiny fraction of that amount
Receiving assistance from a drug corporation to afford an expensive prescription feels a lot like pharma benevolence. Here's why these programs are robbing us blind:
There is a simple and potentially cost-saving question patients may not know they can ask their pharmacists.
WASHINGTON, DC — Seniors are filling fewer prescriptions for brand-named drugs, but they’re spending significantly more because list prices keep going up, according to a new government report. In response, David Mitchell, a cancer patient and founder of Patients For Affordable Drugs, issued the following statement.
In an attempt to encourage and improve transparency, the FDA released a list of more than 50 drug makers accused by generic drug corporations of stalling providing samples that would increase competition and lower prices.
“We have an incredibly powerful, incredibly productive research and development program being run by N.I.H.,” Ameet Sarpatwari, an instructor at Harvard Medical School, said. “Taxpayers put in money that is paying big dividends, and yet we pay higher prices for prescription drugs than any other country. In effect, we have taxpayers paying twice.”